Anzeige
Meldung des Tages: Antimon-Preis verdreifacht – startet jetzt der nächste Rohstoff-Run?

Q32 Bio Aktie News

Aktie
WKN:  A4ZZ0Z ISIN:  US7469641051 US-Symbol:  QTTB Branche:  Biotechnologie Land:  USA
4,42 $
+0,15 $
+3,51%
3,7514 € 18:38:51 Uhr
Depot/Watchlist
Marktkapitalisierung *
33,16 Mio. €
Streubesitz
29,10%
KGV
-0,88
Index-Zuordnung
-

Q32 Bio News

18.02.26 - PR Newswire
Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference PR Newswire
17.02.26 - PR Newswire
Q32 Bio Announces $10.5 Million Registered Direct Offering
Q32 Bio Announces $10.5 Million Registered Direct Offering PR Newswire
01.12.25 - PR Newswire
Q32 Bio Sells Complement Inhibitor ADX-097
Q32 Bio Sells Complement Inhibitor ADX-097 PR Newswire
13.11.25 - PR Newswire
Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update PR Newswire
21.10.25 - PR Newswire
Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata
Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata PR Newswire
28.08.25 - PR Newswire
Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference
Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference PR Newswire
06.08.25 - PR Newswire
Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update PR Newswire
25.06.25 - PR Newswire
Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer
Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer PR Newswire
08.05.25 - PR Newswire
Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update PR Newswire
30.04.25 - PR Newswire
Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata
Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata PR Newswire
16.04.25 - PR Newswire
Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata
Q32 Bio Doses First Patients in Both Part A Open-​Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata PR Newswire
11.03.25 - PR Newswire
Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update
Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update PR Newswire
08.03.25 - PR Newswire
Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting
Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting PR ...
28.02.25 - PR Newswire
Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting
Q32 Bio Announces Late-​Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology ...
26.02.25 - PR Newswire
Q32 Bio to Participate in Upcoming March Investor Conferences
Q32 Bio to Participate in Upcoming March Investor Conferences PR Newswire

Newssuche

Videos

newspaper
18.02.26 -2,78%
Technical Trading: Chance mit 82 Prozent Treffern
Rohöl Long Typ: Turbo Open End WKN: VH65XQ Hebel:6 Laufzeit: OpenEnd Einstieg: Market ... Mehr »
Anzeige

Aktie im Fokus

Antimon-Preis verdreifacht
Antimony Resources Corp
0,4639 €
-2,03%
Antimony Resources Corp Chart
Startet jetzt der nächste Rohstoff-Run?
Mehr zur Aktie »